ReviewJournal of molecular medicine (Berlin, Germany)2011
From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension.
Review in Journal of molecular medicine (Berlin, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies.BioMed research international · 2014Pooled it
- Inhibition of microRNA-30a alleviates vascular remodeling in pulmonary arterial hypertension.Molecular therapy. Nucleic acids · 2021Article
- The Biological Bases of Group 2 Pulmonary Hypertension.International journal of molecular sciences · 2019Review
- miR‑767‑5p inhibits glioma proliferation and metastasis by targeting SUZ12.Oncology reports · 2019Article
- Transgelin as a potential target in the reversibility of pulmonary arterial hypertension secondary to congenital heart disease.Journal of cellular and molecular medicine · 2018Article
- Targeting Pim Kinases and DAPK3 to Control Hypertension.Cell chemical biology · 2018Article
- Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension.American journal of respiratory and critical care medicine · 2018Article
- Elevated microRNA-135a is associated with pulmonary arterial hypertension in experimental mouse model.Oncotarget · 2017Article
- Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.American journal of respiratory and critical care medicine · 2017Review
- Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words.American journal of respiratory and critical care medicine · 2017Article
- Dysregulation of microRNA-214 and PTEN contributes to the pathogenesis of hypoxic pulmonary hypertension.International journal of chronic obstructive pulmonary disease · 2017Article
- Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series).Pulmonary circulation · 2014Review
- Molecular mechanisms of pulmonary arterial remodeling.Molecular medicine (Cambridge, Mass.) · 2014Review
- Nur77 suppresses pulmonary artery smooth muscle cell proliferation through inhibition of the STAT3/Pim-1/NFAT pathway.American journal of respiratory cell and molecular biology · 2014Article
- Signal transduction in the development of pulmonary arterial hypertension.Pulmonary circulation · 2013Review
- Regulation of ca(2+) signaling in pulmonary hypertension.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2013Article
- STAT3 signaling in pulmonary arterial hypertension.JAK-STAT · 2012Review
- Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.Cellular and molecular life sciences : CMLS · 2012Review
- Looking to the future: a new decade of pulmonary arterial hypertension therapy.European respiratory review : an official journal of the European Respiratory Society · 2011Review
- MicroRNAs-control of essential genes: Implications for pulmonary vascular disease.Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Pulmonary arterial hypertension (PAH) is a disease of the pulmonary vasculature characterized by constricted and remodeled pulmonary arteries. This phenomenon is associated with enhanced pulmonary artery smooth muscle cells proliferation and suppressed apoptosis, metabolism shift, inflammation, and several other features that are considered as hallmarks of cancer. Since oncogenes, tumor suppressors, and miRNAs are the major regulators of signaling in the cancer phenotype, we studied if the same type of regulation is operative in PAH. From the discovery of BMPR2 mutation in familial forms of PAH, oncogenic pathways activation like MAPK were identified. Recently, the Src/STAT3/Pim1 axis was also described as playing a critical role in PAH pathogenesis. Moreover, through the down-regulation of miR-204, STAT3 enhances a positive feedback loop sustaining its own activation, showing that miRNA regulation is critical in PAH. Taken together, targeting oncoproteins or miRNAs appear as new therapeutic strategies for PAH. Several oncoprotein inhibitors are already in trials for cancer and could be soon available for PAH. Concerning miRNAs, the youth of this area makes therapies less achievable soon but not less interesting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.